Prospective Randomized Comparative Study of the Effectiveness and Safety of Ultrasound-guided Laser and Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Thyroid Nodule
- Sponsor
- Campus Bio-Medico University
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Percentage of thyroid nodules with volume reduction at 6 and 12 months after treatment
- Last Updated
- 6 years ago
Overview
Brief Summary
The purpose of this study is to prospectively compare percutaneous radiofrequency ablation (RFA) versus percutaneous laser ablation (LA) for the treatment of solid thyroid nodules.
Detailed Description
Nodular thyroid disease is a common clinical problem whose prevalence increases with age and with a more widespread use of thyroid ultrasonography. Although most thyroid nodules are benign and need only periodic monitoring, some may require treatment for associated pressure and/or cosmetic symptoms. Although thyroid surgery is the main therapeutic approach for compressive thyroid nodules, it may be associated with several drawbacks. Long-term levothyroxine suppression treatment in elderly patients with large nodular goiters is unsatisfactory because it is ineffective. Furthermore, it is associated with adverse effects on bones and the cardiovascular system. Nonsurgical, minimally invasive treatment modalities such as percutaneous laser ablation (LA) and radiofrequency ablation (RFA) have been used to treat thyroid nodules. However no studies comparing LA and RFA have been published so far. Aims of the study 1. To evaluate whether LA and RFA cause a reduction ≥50% in the volume of thyroid nodules after 6 months and 1 year follow-up 2. To evaluate whether the features of thyroid nodules as evaluated by thyroid ultrasound, contrast-enhanced ultrasound, power-doppler and core-biopsy influence LA and RFA outcomes 3. To evaluate changes in thyroid function and thyroid autoimmunity after LA and RFA. 4. To evaluate differences between LA and RFA in terms of complications, side effects and tolerability. Patients will be recruited, treated and followed at Santa Maria Goretti Hospital in Latina, Italy, by physicians with expertise in LA and RFA. The scientific coordinator of this study is dr. Silvia Manfrini.
Investigators
Dr. Silvia Manfrini
Medical Doctor
Campus Bio-Medico University
Eligibility Criteria
Inclusion Criteria
- •Solitary thyroid nodule or dominating nodule which is well-identifiable in multinodular goiter.
- •Compressive and /or cosmetic symptoms caused by thyroid nodule or increase in nodule volume \>20% in 1 year even without symptoms
- •A nodule volume ≥ 5 ml
- •Solid nodule (uniformly compact or nearly completely solid, with a liquid component not exceeding 30%);
- •Two thyroid biopsies resulted negative for malignancy
- •Calcitonin levels within normal ranges
Exclusion Criteria
- •Hyperfunctioning lesion as evaluated biochemically and/or by 99mTc scintigraphy
- •Pregnancy
Outcomes
Primary Outcomes
Percentage of thyroid nodules with volume reduction at 6 and 12 months after treatment
Time Frame: 12 months
Differences in the percentage of nodules with greater than 50% base volume reduction at 6 and 12 months
Secondary Outcomes
- Variation in TSH levels after treatment(12 months)
- Histopathological features of Thyroid Nodules as Predictive factor of response to treatment(12 months)
- Basal Volume of Thyroid Nodules as Predictive factor of response to treatment(12 months)
- Variation in AbTPO and AbTg levels after treatment(12 months)
- Tolerability evaluated by McGill Pain Questionnaire(0 and 6 months)
- Complications(Up to 1 year follow-up)
- Quality of Life(6 months and 1 year)